# Eton Lifts 2026 Revenue Outlook Above $175 Million, Targets LIBERVANT Launch By John Kim Canonical URL: https://www.tokenpost.com/news/business/51011 Published: 2026-11-07T19:05:50.000Z Updated: 2026-11-07T19:05:50.000Z Section: Business > Third-quarter 2026 revenue rose 158% year over year to $57.9 million. Eton expects adjusted EBITDA margin above 40%. Eton Pharmaceuticals now projects revenue above $175 million for 2026 and an adjusted EBITDA margin exceeding 40%. It is targeting an April 2027 launch for LIBERVANT. The company recorded third-quarter 2026 revenue of $57.9 million, up 158% year over year. “It was another outstanding quarter for Eton with record revenue, significant margin expansion and strong cash flow generation,” President, CEO and Director Sean Brynjelsen said. LIBERVANT is a diazepam buccal film for treating seizures. Eton's [exclusive license agreement with Aquestive Therapeutics]() covers the drug. The planned launch depends on final FDA approval and resolution of applicable exclusivity restrictions. ## Links in this article - [exclusive license agreement with Aquestive Therapeutics](https://www.tokenpost.com/news/business/31771)